Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births

Fig. 3

Risk of major congenital anomalies in infants, according to maternal exposure to SSRIs. Relative risks and 95% confidence intervals are presented to show the risk of major congenital anomalies among infants born to women with exposure to SSRIs during the first trimester, as compared with the risk among infants born to women without such exposure. SSRIs, selective serotonin reuptake inhibitors

Back to article page